Mirum Pharmaceuticals price to free cash flow MIRM

Market value divided by free cash flow over the last twelve months, since 2025.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 106×; May 2026
Peer median: 46.0×

Mirum Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2026, at 106×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	106×	90.5×	122×
2025	91.9×	75.4×	443×

Against its peers

Companies in Drug Manufacturers - General nearest Mirum Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
MIRMMirum Pharmaceuticals	n/m
KNSAKiniksa Pharmaceuticals International	32.7×
LGNDLigand Pharmaceuticals	46.0×
AMRXAmneal Pharmaceuticals	50.9×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	100×
LQDALiquidia	25.3×
ALKSAlkermes plc.	33.0×
OGNOrganon	6.4×
TGTXTG Therapeutics	477×
PTGXProtagonist Therapeutics	68.6×
Peer median	46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Mirum Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.